MYMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
MyMD Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-5.14. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.57.
MyMD Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-5.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.57.
MyMD Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-1.86. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.74.
During the past 3 years, the average EPS without NRIGrowth Rate was -19.40% per year.
During the past 4 years, MyMD Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was -19.40% per year. The lowest was -19.40% per year. And the median was -19.40% per year.
The historical data trend for MyMD Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MyMD Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Earnings per Share (Diluted) | -7.67 | -25.50 | -11.74 | -5.33 |
MyMD Pharmaceuticals Quarterly Data | ||||||||||||||||
Mar20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Earnings per Share (Diluted) | Get a 7-Day Free Trial | -1.20 | -3.30 | 1.80 | -2.93 | -5.14 |
For the Biotechnology subindustry, MyMD Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where MyMD Pharmaceuticals's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
MyMD Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Diluted Earnings Per Share (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-4 | - | 4.218) | / | 1.542 | |
= | -5.33 |
MyMD Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as
Diluted Earnings Per Share (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends | / | Shares Outstanding (Diluted Average) |
= | (-9.8 | - | 1.202) | / | 2.141 | |
= | -5.14 |
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
MyMD Pharmaceuticals (NAS:MYMD) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of MyMD Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Rivard | officer: EVP of Operations, GC | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Joshua Silverman | director | IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017 |
Caroline C Williams | 10 percent owner | 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Adam Kaplin | officer: Chief Scientific Officer | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Jude Uzonwanne | director | C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Craig Eagle | director | POST OFFICE BOX 4590, NEW YORK NY 10163 |
Chapman Christopher C Jr | director, officer: President, Chief Med. Officer | C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814 |
Ian Rhodes | officer: Interim CFO | 1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824 |
Stuart M Benson | officer: Chief Financial Officer | EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118 |
Hudson Bay Capital Management Lp | 10 percent owner | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Sander Gerber | 10 percent owner | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Robert C Schroeder | director | 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724 |
Howard Yeaton | officer: CEO, CFO | 79 LLOYD ROAD, HOHOKUS NJ 07423 |
Tarbox Richard C Iii | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
Christopher C Schreiber | director | AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086 |
From GuruFocus
By Business Wire Business Wire • 12-06-2022
By Business Wire • 12-06-2023
By Business Wire Business Wire • 12-01-2021
By Business Wire Business Wire • 02-08-2022
By Business Wire Business Wire • 02-21-2023
By Business Wire Business Wire • 08-03-2022
By Business Wire Business Wire • 12-29-2021
By Business Wire Business Wire • 08-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.